Anti TNF- therapy for ulcerative colitis: current status and prospects for the future

被引：152

作者：

Pugliese, Daniela ^{[1
]}

Felice, Carla ^{[1
]}

Papa, Alfredo ^{[1
]}

Gasbarrini, Antonio ^{[1
]}

Rapaccini, Gian Lodovico ^{[1
]}

Guidi, Luisa ^{[1
]}

Armuzzi, Alessandro ^{[1
]}

机构：

[1] Gemelli Hosp Catholic Univ Fdn, IBD Unit, Internal Med & Gastroenterol, Complesso Integrato Columbus, Rome, Italy

来源：

EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2017年 / 13卷 / 03期

关键词：

Ulcerative colitis; anti TNF-; remission; mucosal healing; biosimilar; vedolizumab; INFLAMMATORY-BOWEL-DISEASE; TUMOR-NECROSIS-FACTOR; EVIDENCE-BASED CONSENSUS; CROHNS-DISEASE; MAINTENANCE THERAPY; DOUBLE-BLIND; FACTOR-ALPHA; COMBINATION THERAPY; INFLIXIMAB THERAPY; INDUCTION THERAPY;

D O I：

10.1080/1744666X.2017.1243468

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

071005 [微生物学]; 100108 [医学免疫学];

摘要：

Introduction: Anti TNF- agents have become a significant advance in the management of ulcerative colitis, proving to induce, with rapid onset, clinical and endoscopic remission. However, there is still a considerable unmet medical need in ulcerative colitis.Areas covered: The aim of this review was to summarize the patterns of use and the effectiveness of anti TNF- in ulcerative colitis, highlighting their current position in treatment algorithms. Moreover, we set out a five-year view hypothesizing different treatment strategies.Expert commentary: The rapid onset of action and the effectiveness in inducing mucosal healing are the most important pros of anti TNF-, supporting present and future use. Conversely, the relevant risk of loss of response and the safety profile have raised several concerns. In the future, the advent of different molecular targeting therapies can improve the management of UC patients, evolving to individually tailored strategies.

引用

页码：223 / 233

页数：11

共 107 条

[1]

Fingolimod Therapy in Early Multiple Sclerosis: An Efficacy Analysis of the TRANSFORMS and FREEDOMS Studies by Time Since First Symptom [J].

Agius, Mark ;

Meng, Xiangyi ;

Chin, Peter ;

Grinspan, Augusto ;

Hashmonay, Ronny .

CNS NEUROSCIENCE & THERAPEUTICS, 2014, 20 (05) :446-451

[2]

Amiot A, 2016, CLIN GASTROENTEROL H

[3]

Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases [J].

Amiot, Aurelien ;

Peyrin-Biroulet, Laurent .

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2015, 8 (02) :66-82

[4]

Association Between Tumor Necrosis Factor-α Antagonists and Risk of Cancer in Patients With Inflammatory Bowel Disease (vol 311, pg 2406, 2014) [J].

Andersen, Nynne Nyboe ;

Pasternak, Bjoern ;

Basit, Saima ;

Andersson, Mikael ;

Svanstroem, Henrik ;

Caspersen, Sarah ;

Munkholm, Pia ;

Hviid, Anders ;

Jess, Tine .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (23) :A2406-A2406

[5]

Impact of New Treatments on Hospitalisation, Surgery, Infection, and Mortality in IBD: a Focus Paper by the Epidemiology Committee of ECCO [J].

Annese, Vito ;

Duricova, Dana ;

Gower-Rousseau, Corinne ;

Jess, Tine ;

Langholz, Ebbe .

JOURNAL OF CROHNS & COLITIS, 2016, 10 (02) :216-225

[6]

[Anonymous], 1964, CRIT COMM NEW YORK H

[7]

[Anonymous], 2013, REMICADE INFL PACK I

[8]

[Anonymous], 2015, HUMIRA AD PACK INS

[9]

[Anonymous], 2015, ENT VED PACK INS

[10]

[Anonymous], 2015, SIMPONI GOL PACK INS

← 1 2 3 4 5 6 7 8 9 10 →